Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field of neoantigen-targeted therapies and dedicated to transforming the treatment of each patient’s cancer by directing the immune system towards neoantigens. We have pioneered a proprietary neoantigen platform to develop neoantigen-targeted therapies using two distinct approaches. In NEON / ONE, these neoantigens are specific to each individual. In NEON / SELECT, these neoantigens are shared across subsets of patients and tumor types. Our most advanced product candidate is NEO‑PV‑01, a personal neoantigen vaccine, that is currently being evaluated in a Phase 1b open‑label clinical trial for patients with metastatic melanoma, non‑small cell lung cancer or bladder cancer.
Copyright West LLC. Minimum 15 minutes delayed.
Nov 9, 2018 at 6:00 PM EST
Oct 22, 2018 at 8:00 AM EDT
Oct 19 - Oct 23, 2018
January 3, 2019Neon Therapeutics Provides Business Update and Outlook for 2019
December 6, 2018Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon’s NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma
November 16, 2018Neon Therapeutics Named a Top Place to Work in Massachusetts by The Boston Globe